Unknown

Dataset Information

0

Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study.


ABSTRACT: The best strategy to protect individuals against meningococcal disease is to immunize against multiple serogroups. Immunogenicity, antibody persistence, and safety of the EU-licensed meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) were evaluated in healthy participants aged 11-55 years from the Philippines and Saudi Arabia.In this phase IIb, open, controlled study, 500 participants were randomised (3:1) to receive one dose of MenACWY-TT or a licensed meningococcal polysaccharide vaccine (Men-PS). Functional antibody responses against meningococcal serogroups A, C, W-135, and Y were assessed by a serum bactericidal antibody assay using rabbit complement (rSBA) at Month 0, Month 1, Year 1, Year 2, and Year 3. Vaccine response was defined as an rSBA titre ?32 at Month 1 in participants who were seronegative (rSBA titre <8) pre-vaccination and as at least a four-fold increase in titre in participants who were seropositive pre-vaccination. Solicited symptoms were recorded up to Day 4, safety outcomes up to Month 6, and serious adverse events related to vaccination up to Year 3.Pre-specified criteria for non-inferiority of MenACWY-TT versus Men-PS were met in terms of rSBA vaccine response and incidence of grade 3 general symptoms. At Month 1, 82.7%-96.3% of MenACWY-TT and 69.7%-91.7% in Men-PS recipients had a vaccine response for each serogroup. At Year 3, ?99.1% and ?92.9% of MenACWY-TT recipients retained rSBA titres ?8 and ?128, respectively, as compared to ?86.7% and ?80.0% in the Men-PS group. Both vaccines had a clinically acceptable safety profile, although injection site redness and swelling were more frequent in MenACWY-TT recipients.These results suggest that MenACWY-TT could protect adolescents and adults against meningococcal disease up to three years post-vaccination.This study is registered at http://www.clinicaltrials.gov/NCT00356369.

SUBMITTER: Borja-Tabora C 

PROVIDER: S-EPMC3599520 | biostudies-literature | 2013 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study.

Borja-Tabora Charissa C   Montalban Cecilia C   Memish Ziad A ZA   Van der Wielen Marie M   Bianco Veronique V   Boutriau Dominique D   Miller Jacqueline J  

BMC infectious diseases 20130305


<h4>Background</h4>The best strategy to protect individuals against meningococcal disease is to immunize against multiple serogroups. Immunogenicity, antibody persistence, and safety of the EU-licensed meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) were evaluated in healthy participants aged 11-55 years from the Philippines and Saudi Arabia.<h4>Methods</h4>In this phase IIb, open, controlled study, 500 participants were randomised (3:1) to receive one dose of MenACWY-TT or a li  ...[more]

Similar Datasets

| S-EPMC3979687 | biostudies-literature
| S-EPMC5360140 | biostudies-literature
| S-EPMC4994734 | biostudies-literature
| S-EPMC3631514 | biostudies-literature
| S-EPMC9019543 | biostudies-literature
| S-EPMC8060839 | biostudies-literature
| S-EPMC3634976 | biostudies-literature
| S-EPMC3656081 | biostudies-literature
| S-EPMC4595195 | biostudies-literature
| S-EPMC3933042 | biostudies-literature